Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EADO 2018 /
BRAF/MEK inhibition as adjuvant treatment in melanoma

6th - 9th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.18
Views: 845
Rating:

Dr Jessica Hassel - Heidelberg University Hospital, Heidelberg, Germany

Dr Jessica Hassel speaks with ecancer at the EADO 2018 congress in Barcelona on BRAF/MEK inhibition as adjuvant treatment in melanoma.

Dr Hassel explains BRAF/MEK inhibition reduces the risk to relapse by a half and, from the 4 year results presented recently, there is hope to be able to cure half of patients.

She explains that the treatment is readily available to be prescribed in Europe.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation